SAR302503

Myelofibrosis Battle: Novartis Vs. Sanofi
Seeking Alpha
Tue, 09/10/13 - 04:25 pm
Novartis
Sanofi
myelofibrosis
Jakafi
Incyte
SAR302503
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Yahoo/PR Newswire
Sun, 12/9/12 - 11:32 am
Sanofi
myelofibrosis
SAR302503